• CEO Joe Jimenez says that his review of the viability of Novartis' (NVS) small divisions will probably mean that at least one will eventually be sold. • Three units: animal health, vaccines and OTC medicines won't globally scale so it the best solution for shareholders may be to get rid of them. • He cites the unattractive reimbursement environment as the main challenge for the businesses.
Joe also speaks about quality and how Novartis has the resources to invest in order to establish it. Hey Joe, how about investing in the sub-par generic leadership at East Hanover and improve the quality there!
